Edgestream Partners L.P. purchased a new stake in shares of STERIS plc (NYSE:STE – Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 10,884 shares of the medical equipment provider’s stock, valued at approximately $2,286,000.
Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Wellington Management Group LLP grew its position in STERIS by 21.9% during the second quarter. Wellington Management Group LLP now owns 3,502,897 shares of the medical equipment provider’s stock valued at $737,605,000 after buying an additional 629,532 shares during the period. Janus Henderson Group PLC increased its holdings in STERIS by 25.7% during the first quarter. Janus Henderson Group PLC now owns 1,863,139 shares of the medical equipment provider’s stock valued at $411,995,000 after buying an additional 380,504 shares during the last quarter. Amundi raised its position in STERIS by 43.2% in the first quarter. Amundi now owns 771,092 shares of the medical equipment provider’s stock worth $170,512,000 after acquiring an additional 232,520 shares during the period. Dearborn Partners LLC bought a new position in STERIS in the second quarter worth approximately $23,392,000. Finally, Arrowstreet Capital Limited Partnership raised its position in STERIS by 20.6% in the first quarter. Arrowstreet Capital Limited Partnership now owns 519,511 shares of the medical equipment provider’s stock worth $114,879,000 after acquiring an additional 88,872 shares during the period. Hedge funds and other institutional investors own 94.69% of the company’s stock.
STERIS Stock Performance
Shares of NYSE STE opened at $255.66 on Friday. The company has a debt-to-equity ratio of 0.23, a quick ratio of 1.44 and a current ratio of 2.05. The company has a market cap of $24.83 billion, a P/E ratio of 30.33 and a beta of 0.86. The firm’s fifty day moving average is $227.43 and its two-hundred day moving average is $224.49. STERIS plc has a 52-week low of $195.14 and a 52-week high of $269.44.
STERIS (NYSE:STE – Get Free Report) last announced its quarterly earnings results on Wednesday, November 4th. The medical equipment provider reported $2.94 EPS for the quarter, topping the consensus estimate of $2.68 by $0.26. STERIS had a net margin of 13.41% and a return on equity of 14.80%. The business had revenue of $1.59 billion for the quarter, compared to analysts’ expectations of $1.56 billion. During the same quarter in the previous year, the company earned $2.47 EPS. The business’s quarterly revenue was up 8.8% compared to the same quarter last year. As a group, analysts anticipate that STERIS plc will post 11.46 EPS for the current fiscal year.
STERIS Announces Dividend
The company also recently announced a quarterly dividend, which will be paid on Thursday, December 17th. Stockholders of record on Tuesday, November 17th will be issued a $0.69 dividend. This represents a $2.76 annualized dividend and a dividend yield of 1.1%. The ex-dividend date of this dividend is Tuesday, November 17th. STERIS’s payout ratio is 32.74%.
Analyst Upgrades and Downgrades
STE has been the topic of several analyst reports. Morgan Stanley upgraded shares of STERIS from an “overweight” rating to a “buy” rating in a research note on Friday, November 13th. UBS Group reduced their price objective on STERIS from $275.00 to $270.00 and set a “buy” rating for the company in a research note on Friday, August 7th. Weiss Ratings raised STERIS from a “hold (c)” rating to a “hold (c+)” rating in a report on Monday, November 9th. Wall Street Zen raised STERIS from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 14th. Finally, KeyCorp lifted their target price on STERIS from $269.00 to $284.00 and gave the company an “overweight” rating in a research report on Friday, November 6th. Five analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $283.50.
Read Our Latest Report on STERIS
Insider Buying and Selling
In related news, CFO Karen Burton sold 5,880 shares of the business’s stock in a transaction dated Wednesday, November 11th. The stock was sold at an average price of $255.62, for a total value of $1,503,045.60. Following the sale, the chief financial officer directly owned 12,956 shares in the company, valued at approximately $3,311,812.72. The trade was a 31.22% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Julia Madsen sold 2,046 shares of the stock in a transaction that occurred on Friday, November 13th. The shares were sold at an average price of $260.00, for a total value of $531,960.00. Following the transaction, the vice president directly owned 10,211 shares of the company’s stock, valued at approximately $2,654,860. The trade was a 16.69% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 12,819 shares of company stock worth $3,274,011. Corporate insiders own 1.12% of the company’s stock.
About STERIS
STERIS plc (NYSE: STE) provides infection prevention and procedural products and services for healthcare, pharmaceutical, research, and other industries. Its offerings include sterilizers, washers and other equipment used to clean and sterilize medical devices and surgical instruments, as well as products for operating rooms and endoscopy procedures. The company also provides equipment installation, maintenance, repair, and training, along with contract sterilization and laboratory testing services.
See Also
- Five stocks we like better than STERIS
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Receive News & Ratings for STERIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STERIS and related companies with MarketBeat.com's FREE daily email newsletter.
